Spots Global Cancer Trial Database for Study of AK119 in Subjects With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of AK119 in Subjects With Advanced Solid Tumors
Official Title: A Phase I, Multicenter, Open-Label, Dose-escalation and Dose-exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of of AK119 (CD73) in Subjects With Advanced Solid Tumors
Study ID: NCT05173792
Conditions
Interventions
Study Description
Brief Summary: This is Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Subjects with Advanced or Metastatic Solid Tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fudan University Zhongshan Hospital, Shanghai, , China
Tianjin Medical University Cancer Institute & Hospital, Tianjin, , China
Contact Details
Name: Jihui Hao, PhD
Affiliation: Tianjin Medical University Cancer Insitute & Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Tianshu Liu
Affiliation: Shanghai Zhongshan Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
